MA47268A - Anticorps anti-gpc3 - Google Patents

Anticorps anti-gpc3

Info

Publication number
MA47268A
MA47268A MA047268A MA47268A MA47268A MA 47268 A MA47268 A MA 47268A MA 047268 A MA047268 A MA 047268A MA 47268 A MA47268 A MA 47268A MA 47268 A MA47268 A MA 47268A
Authority
MA
Morocco
Prior art keywords
gpc3
antibody anti
antibody
Prior art date
Application number
MA047268A
Other languages
English (en)
French (fr)
Inventor
Tetsuya Nakatsura
Keigo Saito
Yukimi Sakoda
Koji Tamada
Original Assignee
Nat Cancer Ct
Noile Immune Biotech Inc
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Noile Immune Biotech Inc, Univ Yamaguchi filed Critical Nat Cancer Ct
Publication of MA47268A publication Critical patent/MA47268A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
MA047268A 2017-01-10 2018-01-10 Anticorps anti-gpc3 MA47268A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017001732 2017-01-10

Publications (1)

Publication Number Publication Date
MA47268A true MA47268A (fr) 2019-11-20

Family

ID=62839598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047268A MA47268A (fr) 2017-01-10 2018-01-10 Anticorps anti-gpc3

Country Status (14)

Country Link
US (3) US11718663B2 (OSRAM)
EP (1) EP3569709A4 (OSRAM)
JP (4) JP6579640B2 (OSRAM)
KR (1) KR102564097B1 (OSRAM)
CN (2) CN110177876B (OSRAM)
AU (1) AU2018208191B2 (OSRAM)
BR (1) BR112019013947A2 (OSRAM)
CA (1) CA3049189A1 (OSRAM)
EA (1) EA201991385A1 (OSRAM)
IL (2) IL300270A (OSRAM)
MA (1) MA47268A (OSRAM)
MX (1) MX2019008221A (OSRAM)
TW (2) TWI780102B (OSRAM)
WO (1) WO2018131586A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102564097B1 (ko) * 2017-01-10 2023-08-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 항 gpc3 항체
TWI809130B (zh) 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
WO2020017479A1 (ja) * 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
AU2019354395A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
CN111040036B (zh) * 2018-10-12 2023-10-20 上海卡智生物技术有限公司 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
JP2022536975A (ja) 2019-06-21 2022-08-22 カイト ファーマ インコーポレイテッド ＴＧＦ－β受容体及び使用方法
CN112574297B (zh) * 2019-09-27 2022-06-24 上海生物制品研究所有限责任公司 抗神经氨酸酶的单克隆抗体及其应用
CN113227148B (zh) * 2019-12-05 2022-11-01 上海翰森生物医药科技有限公司 抗gpc3抗体、其抗原结合片段及其医药用途
CN115960205A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
AU2021224793A1 (en) * 2020-02-17 2022-09-01 Board Of Regents, The University Of Texas System Human 4-1BB agonist antibodies and methods of use thereof
EP4110912A4 (en) * 2020-02-27 2024-07-10 Legend Biotech Ireland Limited ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND METHODS OF USE THEREOF
EP4121516A4 (en) * 2020-03-18 2024-06-05 Eutilex Co., Ltd. Gpc3 car-t cell compositions and methods of making and using the same
EP4121517A4 (en) * 2020-03-18 2024-08-07 Eutilex Co., Ltd. IL-18-SECRETING GPC3 CAR-T CELLS AND METHODS OF MAKING AND USING THE SAME
EP4247426A4 (en) * 2020-11-18 2024-10-23 Memorial Sloan Kettering Cancer Center MULTISPECIFIC ANTI-GPA33 ANTIBODIES AND THEIR USES
CN114573702A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
KR20220080381A (ko) * 2020-12-07 2022-06-14 (주)이노베이션바이오 Gpc3에 특이적인 항체 및 이의 용도
CN113072643B (zh) * 2021-03-22 2021-10-15 南京医科大学 抗Glypican-3耐酸性全人源抗体、其免疫毒素、其嵌合抗原受体细胞及应用
TW202302635A (zh) * 2021-03-28 2023-01-16 美商伊米若梅有限公司 Ｉｌ－３８專一性抗體
KR20240019811A (ko) * 2021-06-08 2024-02-14 카이트 파마 인코포레이티드 Gpc3 결합 분자
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
CN113527500B (zh) * 2021-07-16 2022-09-20 蒋小滔 一种磷脂酰肌醇蛋白聚糖3的全人源单克隆抗体、其嵌合抗原受体及应用
WO2023286841A1 (ja) * 2021-07-16 2023-01-19 ノイルイミューン・バイオテック株式会社 キメラ抗原受容体、前記受容体を発現する細胞、前記細胞を含む医薬組成物、前記細胞の製造方法、及び、前記キメラ抗原受容体をコードする塩基配列を含むポリヌクレオチド又はベクター
IL310866A (en) * 2021-08-19 2024-04-01 Adicet Therapeutics Inc Methods for detection of membrane bound glypican-3
CN116063527A (zh) * 2021-09-30 2023-05-05 南京北恒生物科技有限公司 靶向间皮素的抗体及其用途
CN116004639A (zh) * 2022-08-18 2023-04-25 武汉生之源生物科技股份有限公司 一种磷脂酰肌醇蛋白聚糖3的n末端片段、编码基因、多克隆抗体及其制备方法和应用
JP7295324B1 (ja) 2022-11-30 2023-06-20 株式会社合同資源 フッ化物イオンとリン酸イオンの選択除去性を持つ無機系凝集剤によるヨウ素成分含有水溶液の製造方法
WO2024118866A1 (en) * 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024177972A2 (en) * 2023-02-20 2024-08-29 The Wistar Institute Of Anatomy And Biology Antibody-cytokine chimeras
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118063612B (zh) * 2024-04-18 2024-07-26 上海宏成药业有限公司 抗ror1抗体或其抗原结合片段及其用途
CN119978147B (zh) * 2025-02-26 2025-11-11 中山大学 一种用于富集酪氨酸n-乙酰半乳糖胺修饰位点的磁珠及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255162T1 (de) 1983-01-13 2003-12-15 Max Planck Gesellschaft Transgene dicotyledone pflanzenzellen und pflanzen
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
EP0429093B1 (de) 1984-05-11 2001-08-08 Syngenta Participations AG Transformation von Pflanzenerbgut
JPS62275650A (ja) 1986-05-23 1987-11-30 Hatsuho Seika Kk 膨張菓子の製造方法
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2002330482A1 (en) * 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
EP2216046B1 (en) 2004-07-09 2014-03-12 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
ES2666550T3 (es) 2011-04-19 2018-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
EA201492163A1 (ru) * 2012-06-08 2015-08-31 Гленмарк Фармасьютикалс С.А. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
US20150284452A1 (en) * 2012-11-13 2015-10-08 Iogenetics, Llc Antimicrobial compositions
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CN105849562B (zh) * 2013-12-24 2019-08-16 中外制药株式会社 可溶性gpc3蛋白质的测定方法
BR112016027222A2 (pt) * 2014-05-22 2018-01-30 Genentech Inc anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
WO2016049459A1 (en) 2014-09-26 2016-03-31 Baylor College Of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
HUE046710T2 (hu) 2014-10-09 2020-03-30 Univ Yamaguchi CAR expressziós vektor és CAR-t expresszáló T-sejtek
JP6558091B2 (ja) 2015-06-15 2019-08-14 大日本印刷株式会社 注出口組合体、注出口組合体付容器、及び充填体
KR102564097B1 (ko) * 2017-01-10 2023-08-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 항 gpc3 항체

Also Published As

Publication number Publication date
IL300270A (en) 2023-04-01
CN116102651A (zh) 2023-05-12
US12129291B2 (en) 2024-10-29
IL267797A (en) 2019-10-31
US11718663B2 (en) 2023-08-08
WO2018131586A1 (ja) 2018-07-19
TW202309098A (zh) 2023-03-01
IL267797B1 (en) 2023-03-01
JP6647675B2 (ja) 2020-02-14
JP7389424B2 (ja) 2023-11-30
JPWO2018131586A1 (ja) 2019-11-07
US10781249B2 (en) 2020-09-22
MX2019008221A (es) 2019-12-09
BR112019013947A2 (pt) 2020-02-11
AU2018208191A1 (en) 2019-07-04
JP2019216739A (ja) 2019-12-26
NZ754830A (en) 2024-10-25
TWI780102B (zh) 2022-10-11
CN110177876A (zh) 2019-08-27
CA3049189A1 (en) 2018-07-19
EP3569709A4 (en) 2020-08-19
EP3569709A1 (en) 2019-11-20
CN110177876B (zh) 2023-03-31
AU2018208191B2 (en) 2024-09-12
TWI831365B (zh) 2024-02-01
US20190359698A1 (en) 2019-11-28
IL267797B2 (en) 2023-07-01
KR102564097B1 (ko) 2023-08-04
TW201831516A (zh) 2018-09-01
US20190367634A1 (en) 2019-12-05
EA201991385A1 (ru) 2019-12-30
US20240018224A1 (en) 2024-01-18
JP6579640B2 (ja) 2019-09-25
JP2022191318A (ja) 2022-12-27
KR20190101989A (ko) 2019-09-02
JP2020074776A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3903817A4 (en) NOVEL ANTI-CRR8 ANTIBODY
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3423089A4 (en) ANTI-Tigit ANTIBODY
MA52366A (fr) Anticorps anti-tl1a optimisés
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3626825A4 (en) ANTI-CDH6 ANTIBODIES AND ANTI-CDH6 ANTIBODY INGREDIENT CONJUGATE
EP3883970A4 (en) ANTI-B7-H3 ANTIBODIES
EP3334757A4 (en) ANTI-Tigit ANTIBODY
EP3297671A4 (en) ANTI-ROR1 ANTIBODY
MA46041A (fr) Anticorps anti-tim -3
MA50352A (fr) Anticorps multispécifiques
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA49749A (fr) Anticorps anti-cd137
MA46057A (fr) Anticorps anti-ctla4
MA47472A (fr) Anticorps
MA46272A (fr) Anticorps anti-cd27
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3526247A4 (en) Anti-il1-rap antibodies
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
EP3399992A4 (en) SELF-NETWORKING ANTIBODIES
EP3383915A4 (en) PD-1 ANTIBODY